261 Endometrial Cancer Clinical Trials Recruiting Now (October 2026): MMR Status, Dostarlimab, T-DXd, Selinexor, RAINBO Molecular Classification, MDM2 Navtemadlin

Last updated: October 24, 2026

Answer a few questions to find clinical trials matched to your specific Endometrial Cancer situation.

A thorough search takes ~15 minutes — we'll email your results. No sign-up.

Current Clinical Trial Landscape

Active research areas in 2026:

IO + chemo as new standard first-line: pembrolizumab (NRG-GY018) and dostarlimab (RUBY) both practice-changing
ADCs: trastuzumab deruxtecan (T-DXd) for HER2+, sacituzumab tirumotecan, puxitatug samrotecan (B7-H4)
Lenvatinib + pembrolizumab for pMMR/MSS disease (KEYNOTE-775)
Molecular classification-guided treatment (POLE, dMMR, p53, NSMP subtypes)
Fertility-sparing approaches for early-stage endometrioid carcinoma

Standard of care: First-line advanced: carboplatin/paclitaxel + pembrolizumab (FDA Jun 2024) or dostarlimab (FDA Aug 2024), regardless of MMR status; or + durvalumab for dMMR tumors (FDA Jun 2024). Second-line dMMR: pembrolizumab or dostarlimab monotherapy. Second-line pMMR: lenvatinib + pembrolizumab. MMR/MSI status and p53 mutation are key biomarkers.

Recruiting Trials by Treatment Setting

Adjuvant — Molecular-Classification-Guided

The biggest adjuvant story in endometrial cancer is treatment-tailoring by molecular classification (TCGA-style 4-group profiling: p53abn / MMRd / NSMP / POLEmut):

NCT05255653 - RAINBO (Leiden University): umbrella Phase 2/3 program assigning patients to one of four sub-trials based on tumor molecular profile: p53abn-RED, MMRd-GREEN, NSMP-ORANGE, POLEmut-BLUE. Landmark adjuvant trial for molecular-classification-guided EC treatment.
NCT06712472 - RAINBO-RED: maintenance olaparib vs observation in p53abn EC after adjuvant treatment (Phase 3, Gustave Roussy — connected to the broader RAINBO umbrella).
NCT05640999 - Adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (Phase 2, molecular-classification-guided).

Advanced / Recurrent — First-Line

IO + chemo is standard. Trials test ADC additions and novel combinations:

ADC combinations (cross-class hubs: HER2 ADCs · TROP2 ADCs):
- NCT06952504 - TroFuse-033: sacituzumab tirumotecan (TROP2 ADC) + pembrolizumab vs placebo + pembrolizumab (Phase 3, Merck)
- NCT06989112 - DESTINY-Endometrial01: T-DXd + rilvegostomig for HER2+ endometrial cancer (Phase 3, AstraZeneca)
- NCT07044336 - Puxitatug samrotecan (AZD8205, B7-H4 ADC) vs chemo in B7-H4-selected endometrial cancer (Phase 3, AstraZeneca)
Novel IO combinations:
- NCT06340568 - Fern-EC-01: investigational therapy vs chemo in advanced endometrial cancer (Phase 3, BioNTech)
- NCT06584032 - Fruquintinib + sintilimab for advanced endometrial cancer (Phase 3, HUTCHMED)

Advanced / Recurrent — Second-Line and Beyond

After first-line IO+chemo failure, HER2-targeted, ADC, and novel agents:

HER2-targeted:
- NCT05256225 - Trastuzumab/pertuzumab added to chemo for HER2+ uterine cancers (Phase 3, NCI) — active, not recruiting as of October 2026
- NCT07022483 - T-DXd vs standard chemo for HER2-expressing endometrial cancer (Phase 3, Daiichi Sankyo)
Novel agents:
- NCT07166094 - RAINFOL-03: Rina-S (rinatabart sesutecan, FRα ADC) vs investigator's choice in recurrent endometrial cancer (Phase 3, Genmab)
- NCT07198074 - Bevacizumab + carboplatin/paclitaxel for recurrent endometrial cancer (Phase 3, NCI)
Biomarker-directed and other recurrent-disease trials:
- NCT05797831 - Navtemadlin (MDM2 antagonist) as maintenance in TP53WT advanced or recurrent endometrial cancer who responded to chemotherapy (Phase 2/3, Kartos). Another TP53WT-targeted maintenance approach distinct from selinexor's XPO1 mechanism.
- NCT07286331 - Mocertatug rezetecan (Mo-Rez, antibody-drug conjugate) vs chemotherapy in advanced/recurrent endometrial cancer (Phase 3)
- NCT05489211 - Datopotamab deruxtecan (Dato-DXd, TROP2 ADC) as monotherapy and in combinations in advanced/recurrent endometrial cancer (Phase 2).
- NCT07594015 - Pembrolizumab + lenvatinib in mismatch-repair-proficient (pMMR) recurrent endometrial cancer (Phase 2, the KEYNOTE-775 combination in the pMMR setting).
- NCT06413992 - Camrelizumab (PD-1) + fluzoparib (PARP) for TP53-mutated recurrent/metastatic endometrial cancer (Phase 2, biomarker-directed IO + PARP).
- NCT06518564 - Avelumab (PD-L1) + M1774 (tuvusertib, ATR inhibitor) in ARID1A-mutated recurrent endometrial cancer (Phase 2, biomarker-directed). — active, not recruiting as of October 2026
- NCT06925724 - Ivonescimab (PD-1/VEGF bispecific) in endometrial and cervical cancer (Phase 2).
- NCT07209449 - Elacestrant (oral SERD) alone or with abemaciclib (CDK4/6) in ER+ endometrial cancer (Phase 2).
- NCT04469764 - Abemaciclib (CDK4/6 inhibitor) for recurrent endometrial (and ovarian) cancer (Phase 2).

Fertility-Sparing Treatment

For young women with early-stage endometrioid carcinoma who want to preserve fertility:

- NCT07319429 - FEMUS: refining fertility-sparing treatment based on molecular classification (Phase 2/3, Fudan University)
- NCT06379113 - GnRHa + letrozole in obese progestin-insensitive endometrial cancer (Phase 3)
- NCT05316935 - GnRHa + letrozole in non-obese progestin-insensitive endometrial cancer (Phase 3)

Showing selected notable trials. View all 261 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find endometrial cancer clinical trials I'm eligible for?

Enter your endometrial cancer details into ClinTrialFinder — including MMR/MSI status (dMMR vs pMMR), p53 mutation, HER2 status, and prior treatments. The AI matches you with trials based on your specific profile in minutes.

What endometrial cancer trials are currently recruiting?

There are 261 recruiting interventional trials for endometrial cancer in October 2026 including 26 Phase 3 studies. Recent Phase 3: ARTIST adding bevacizumab to carbo/paclitaxel NCT07198074, Puxitatug Samrotecan AZD8205 (B7-H4 ADC) Bluestar-Endo NCT07044336, Phesgo/Herceptin Hylecta HER2+ endometrial NCT05256225, MK-2870 + pembro vs pembro NCT06952504, Rina-S NCT07166094. Active classes: checkpoint immunotherapy combinations (pembrolizumab, dostarlimab), ADCs (T-DXd, sacituzumab tirumotecan, Puxitatug Samrotecan B7-H4, Rina-S folate receptor — see HER2 ADCs hub), lenvatinib combinations, MMR/MSI-based stratification (RAINBO molecular classification), MDM2 navtemadlin, selinexor, and fertility-sparing approaches.

Find Endometrial Cancer Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials